Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans

Nature Genetics

Volumn 37, Issue 8, 2005, Pages 835-843

  Hillebrandt, Sonja ^a,b   Wasmuth, Hermann E ^a   Weiskirchen, Ralf ^a   Hellerbrand, Claus ^c   Keppeler, Hildegard ^a,b   Werth, Alexa ^a   Schirin Sokhan, Ramin ^a   Wilkens, Gabriele ^a   Geier, Andreas ^a   Lorenzen, Johann ^a   Köhl, Jörg ^d   Gressner, Axel M ^a   Matern, Siegfried ^a   Lammert, Frank ^a,b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A RECEPTOR; DNA; G PROTEIN COUPLED RECEPTOR; MESSENGER RNA;

ADULT; AGED; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFOCAL LASER MICROSCOPY; FEMALE; FIBROGENESIS; GENE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEPATITIS C; HUMAN; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE TRAIT; QUANTITATIVE TRAIT LOCUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CHROMOSOME MAPPING; COMPLEMENT C5; GENOTYPE; HUMANS; LIVER CIRRHOSIS; MICE; MICE, INBRED STRAINS; POLYMORPHISM, GENETIC; QUANTITATIVE TRAIT LOCI;

ANIMALIA; HEPATITIS C VIRUS;

EID: 23044477984     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng1599     Document Type: Article

References (50)

1. Poynard, T., Yuen, M.F., Ratziu, V. & Lai, C.L. Viral hepatitis C. Lancet 362, 2095-2100 (2003).
2. Friedman, S.L. Liver fibrosis - from bench to bedside. J. Hepatol. 38, S38-S53 (2003).
3. Poynard, T., Bedossa, P. & Opolon, P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349, 825-832 (1997).
4. Bataller, R. & Brenner, D.A. Liver fibrosis. J. Clin. Invest. 115, 209-218 (2005).
5. Hillebrandt, S., Goos, C., Matern, S. & Lammert, F. Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology 123, 2041-2051 (2002).
6. Shi, Z., Wakil, A.E. & Rockey, D.C. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc. Natl. Acad. Sci. USA 94, 10663-10668 (1997).
7. Complex Trait Consortium. The nature and identification of quantitative trait loci: a community's view. Nat. Rev. Genet. 4, 911-916 (2003).
8. Pletcher, M.T. et al. Use of a dense single nucleotide polymorphism map for in silico mapping in the mouse. PLoS Biol. 2, e393 (2004).
9. Wetsel, R.A., Fleischer, D.T. & Haviland, D.L. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5′-exon. J. Biol. Chem. 265, 2435-2440 (1990).
10. Churchill, G.A. & Doerge, R.W. Empirical threshold values for quantitative trait mapping. Genetics 138, 963-971 (1994).
11. Zondervan, K.T. & Cardon, L.R. The complex interplay among factors that influence allelic association. Nat. Rev. Genet. 5, 89-100 (2004).
12. Zhang, Y., Buchholz, F., Muyrers, J.P. & Stewart, A.F. A new logic for DNA engineering using recombination in Escherichia coli. Nat. Genet. 20, 123-128 (1998).
13. Köhl, J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol. Immunol. 38, 175-187 (2001).
14. Schlaf, G. et al. Expression and induction of anaphylatoxin C5a receptors in the rat liver. Histol. Histopathol. 18, 299-308 (2003).
15. Friedman, S.L. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Pract. Gastroenterol. Hepatol. 1, 98-105 (2004).
16. Konteatis, Z.D. et al. Development of C5a receptor antagonists. Differential loss of functional responses. J. Immunol. 153, 4200-4205 (1994).
17. Strey, C.W. et al. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J. Exp. Med. 198, 913-923 (2003).
18. Walport, M.J. Complement. Second of two parts. N. Engl. J. Med. 344, 1140-1144 (2001).
19. Whaley, K. & Schwaeble, W. Complement and complement deficiencies. Semin. Liver Dis. 17, 297-310 (1997).
20. Ellison, R.T., Horsburgh, C.R. & Curd, J. Complement levels in patients with hepatic dysfunction. Dig. Dis. Sci. 35, 231-235 (1990).
21. Flint, J., Valdar, W., Shifman, S. & Mott, R. Strategies for mapping and cloning quantitative trait genes in rodents. Nat. Rev. Genet. 6, 271-284 (2005).
22. The International HapMap Consortium. The International HapMap Project. Nature 426, 789-796 (2003).
23. Wasmuth, H.E., Matern, S. & Lammert, F. From genotypes to haplotypes in hepatobiliary diseases: one plus one equals (sometimes) more than two. Hepatology 39, 604-607 (2004).
24. Smithies, O. Many little things: one geneticist's view of complex diseases. Nat. Rev. Genet. 6, 419-425 (2005).
25. Neumann, U.P. et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J. Hepatol. 41, 830-836 (2004).
26. Czermak, B.J. et al. Role of complement in in vitro and in vivo lung inflammatory reactions. J. Leukoc. Biol. 64, 40-48 (1998).
27. Phan, S.H. & Thrall, R.S. Inhibition of bleomycin-induced pulmonary fibrosis by cobra venom factor. Am. J. Pathol. 107, 25-28 (1982).
28. Sheerin, N.S. & Sacks, S.H. Leaked protein and interstitial damage in the kidney: is complement the missing link? Clin. Exp. Immunol. 130, 1-3 (2002).
29. Finch, A.M. et al. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J. Med. Chem. 42, 1965-1974 (1999).
30. Mastellos, D., Papadimitriou, J.C., Franchini, S., Tsonis, P.A. & Lambris, J.D. A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J. Immunol. 166, 2479-2486 (2001).
31. Huber-Lang, M.S. et al. Protection of innate immunity by CSaR antagonist in septic mice. FASEB J. 16, 1567-1574 (2002).
32. Hillmen, P. et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 350, 552-559 (2004).
33. Hawlisch, H. et al. C5a negatively regulates Toll-like receptor 4-induced immune responses. Immunity 22, 415-426 (2005).
34. H2 paradigm. Nat. Rev. Immunol. 4, 583-594 (2004).
35. Korstanje, R. & Paigen, B. From QTL to gene: the harvest begins. Nat. Genet. 31, 235-236 (2002).
36. Poupon, R. & Poupon, R.E. Primary biliary cirrhosis. In Hepatology: A Textbook of Liver Diseases vol. 2 (eds. Zakim, D. & Boyer, TD.) 1329-1365 (W.B. Saunders, Philadelphia, 1996).
37. Senaldi, G. et al. Activation of the complement system in primary sclerosing cholangitis. Gastroenterology 97, 1430-1434 (1989).
38. Geier, A. et al. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C. Liver Int. 24, 285-294 (2004).
39. Schulz, K.F. & Grimes, D.A. Case-control studies: research in reverse. Lancet 359, 431-434 (2002).
40. Wasmuth, H.E. et al. CC Chemokine Receptor 5 Δ32 polymorphism in two independent cohorts of HCV infected patients without hemophilia. J. Mol. Med. 82, 64-69 (2004).
41. Manly, K.F. & Olson, J.M. Overview of QTL mapping software and introduction to Map Manager QT Mamm. Genome 10, 327-334 (1999).
42. Haley, C.S. & Knott, S.A. A simple regression method for mapping quantitative trait loci in line crosses using flanking markers. Heredity 69, 315-324 (1992).
43. Stephens, M. & Donnelly, P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73, 1162-1169 (2003).
44. Sebastiani, P. et al. Minimal haplotype tagging. Proc. Natl. Acad. Sci. USA 100, 9900-9905 (2003).
45. Desmet, V.J., Gerber, M., Hoofnagle, J.H., Manns, M. & Scheuer, P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19, 1513-1520 (1994).
46. Imbert-Bismut, F. et al. for the MULTIVIRC group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357, 1069-1075 (2001).
47. Fehrenbach, H., Weiskirchen, R., Kasper, M. & Gressner, A.M. Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology 34, 943-952 (2001).
48. Riedemann, N.C. et al. Increased C5a receptor expression in sepsis. J. Clin. Invest. 110, 101-108 (2002).
49. Sasieni, P.D. From genotypes to genes: doubling the sample size. Biometrics 53, 1253-1261 (1997).
50. Elston, R.C. & Forthofer, R. Testing for Hardy-Weinberg equilibrium in small samples. Biometrics 33, 536-542 (1977).